Recerca > Càncer

Grup de recerca de biomarcadors en càncer (GReBiC)

Nombre de publicacions
495
Cercador de publicacions

  • Sastre, J.; de la Orden, V.; Martinez, A.; Bando, I.; Santamaria, I.; Bellosillo Paricio, B.; Palanca, S.; Peligros, I.; Mediero, B.; Llovet, P.; Moreno, V.; Vieitez, J. M.; Garcia-Alfonso, P.; Gil, S.; Ortiz Morales, M. J.; Salud Salvia, M. A.; Quintero, G.; Gesto, F. A.; Aranda Aguilar, E.; Diaz Rubio, E.

    Circulating tumor cells (CTCs), molecular alterations and their correlation with characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated in the Spanish TTD VISN & Uacute; Program

    ANNALS OF ONCOLOGY 28 -. .

  • Castelblanco, E.; Hernandez, M.; Castelblanco, A.; Esquerda, A.; Mollo, A.; Ramirez-Morros, A.; Franch-Nadal, J.; Fernandez-Real, J. M.; Mauricio, D.

    Low-grade inflammatory marker profile is mainly driven by adiposity-related characteristics in patients with LADA, type 1 and type 2 diabetes

    Diabetologia 60 200-200. .

  • Novell, A; Morales, S; Valls J; Panades, MJ; Salud, A; Iglesias, E; Vilardell, F; Matias-Guiu, X; Llombart-Cussac, A

    Novel biomarkers in primary breast core biopsies to predict poor response to neoadjuvant chemotherapy and appearance of metastases

    HISTOLOGY AND HISTOPATHOLOGY 32 909-915. .

    [doi:10.14670/HH-11-849]

  • Porcel, JM; Civit, C; Esquerda, A; Salud, A; Bielsa, S

    Utility of CEA and CA 15-3 measurements in non-purulent pleural exudates in the diagnosis of malignancy: A single-center experience

    ARCHIVOS DE BRONCONEUMOLOGIA 53 427-431. .

    [doi:10.1016/j.arbres.2016.12.013]

  • Porcel, JM; Pardina, M; Aleman, C; Pallisa, E; Light, RW; Bielsa, S

    Computed tomography scoring system for discriminating between parapneumonic effusions eventually drained and those cured only with antibiotics

    RESPIROLOGY 22 1199-1204. .

    [doi:10.1111/resp.13040]

  • Porcel, JM

    Persistent benign pleural effusion

    REVISTA CLINICA ESPANOLA 217 336-341. .

    [doi:10.1016/j.rce.2017.03.008]

  • von Minckwitz G; Procter M; de Azambuja E; Zardavas D; Benyunes M; Viale G; Suter T; Arahmani A; Rouchet N; Clark E; Knott A; Lang I; Levy C; Yardley DA; Bines J; Gelber RD; Piccart M; Baselga J; APHINITY Steering Committee and Investigators

    Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

    NEW ENGLAND JOURNAL OF MEDICINE 377 122-131. .

    [doi:10.1056/NEJMoa1703643]

  • Porcel, JM

    Pleural effusions in acute idiopathic pericarditis and postcardiac injury syndrome

    Current Opinion in Pulmonary Medicine 23 346-350. .

    [doi:10.1097/MCP.0000000000000383]

  • Pineda, E; Salud, A; Vila-Navarro, E; Safont, MJ; Llorente, B; Aparicio, J; Vera, R; Escudero, P; Casado, E; Bosch, C; Bohn, U; Perez-Carrion, R; Carmona, A; Ayuso, JR; Ripolles, T; Bouzas, R; Gironella, M; Garcia-Albeniz, X; Feliu, J; Maurel, J

    Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial

    TUMOR BIOLOGY 39 -. .

    [doi:10.1177/1010428317705509]

  • Porcel, JM

    Evidence-based clinical diagnosis: the example of coronary chest pain

    REVISTA CLINICA ESPANOLA 217 260-262. .

    [doi:10.1016/j.rce.2017.02.011]

  • Baselga, J; Morales, SM; Awada, A; Blum, JL; Tan, AR; Ewertz, M; Cortes, J; Moy, B; Ruddy, KJ; Haddad, T; Ciruelos, EM; Vuylsteke, P; Ebbinghaus, S; Im, E; Eaton, L; Pathiraja, K; Gause, C; Mauro, D; Jones, MB; Rugo, HS

    A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

    BREAST CANCER RESEARCH AND TREATMENT 163 535-544. .

    [doi:10.1007/s10549-017-4199-3]

  • Mateo, F; Arenas, EJ; Aguilar, H; Serra-Musach, J; de Garibay, GR; Boni, J; Maicas, M; Du, S; Iorio, F; Herranz-Ors, C; Islam, A; Prado, X; Llorente, A; Petit, A; Vidal, A; Catala, I; Soler, T; Venturas, G; Rojo-Sebastian, A; Serra, H; Cuadras, D; Blanco, I; Lozano, J; Canals, F; Sieuwerts, AM; de Weerd, V; Look, MP; Puertas, S; Garcia, N; Perkins, AS; Bonifaci, N; Skowron, M; Gomez-Baldo, L; Hernandez, V; Martinez-Aranda, A; Martinez-Iniesta, M; Serrat, X; Ceron, J; Brunet, J; Barretina, MP; Gil, M; Falo, C; Fernandez, A; Morilla, I; Pernas, S; Pla, MJ; Andreu, X; Segui, MA; Ballester, R; Castella, E; Nellist, M; Morales, S; Valls, J; Velasco, A; Matias-Guiu, X; Figueras, A; Sanchez-Mut, JV; Sanchez-Cespedes, M; Cordero, A; Gomez-Miragaya, J; Palomero, L; Gomez, A; Gajewski, TF; Cohen, EEW; Jesiotr, M; Bodnar, L; Quintela-Fandino, M; Lopez-Bigas, N; Valdes-Mas, R; Puente, XS; Viñals F; Casanovas, O; Graupera, M; Hernandez-Losa, J; Ramón Y Cajal S; Garcia-Alonso, L; Saez-Rodriguez, J; Esteller, M; Sierra, A; Martin-Martin, N; Matheu, A; Carracedo, A; Gonzalez-Suarez, E; Nanjundan, M; Cortes, J; Lazaro, C; Odero, MD; Martens, JWM; Moreno-Bueno, G; Barcellos-Hoff, MH; Villanueva, A; Gomis, RR; Pujana, MA

    Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

    ONCOGENE 36 2737-2749. .

    [doi:10.1038/onc.2016.427]